Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials click here
Tuesday, May 8, 2012
Risk of Liver-Related Deaths Twice as High With Chronic Hep B Versus Hep C
“This study emphasizes the need for a more aggressive approach to the prevention, diagnosis and treatment of [chronic HBV infection], including increasing vaccination rates among all [hep B] susceptible individuals,” writes Oluwaseun Falade-Nwulia, MD, of Johns Hopkins University and her Multicenter AIDS Cohort Study (MACS) colleagues. “This is especially true in Asian and African countries where there is a high prevalence of [chronic HBV], HIV infection and HIV/HBV coinfection.”